Hepatitis C drug pricing weighs on Gilead

Gilead said in its earnings report that it gave insurers steeper-than-expected discounts on its hepatitis C drugs.

This entry was posted in Biotech & Pharmaceuticals, Drugs, NBR Show Clips. Bookmark the permalink.

Leave a Reply